$-0.07
(Market cap
$211 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.1
-
Face value
--
-
Shares outstanding
37,736,237
5 Years Aggregate
CFO
$-115.08 Mln
EBITDA
$-147.04 Mln
Net Profit
$-146.91 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
| 380.7 | 2.4 | 26.6 | 398.2 | -28.6 | -- | -- |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
| -17.4 | -93.1 | 115.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
5.5 | 210.6 | 0.0 | -36.3 | -- | -56.3 | -- | 2.9 |
| 82.7 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 71.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.9 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 363.8 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 538.7 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 583.2 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 146.5 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout AN2 Therapeutics Inc (ANTX)
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for... patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California. Read more
-
Co-founder & Chairman of the Board
Mr. Joseph S. Zakrzewski
-
Co-founder & Chairman of the Board
Mr. Joseph S. Zakrzewski
-
Headquarters
Menlo Park, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for AN2 Therapeutics Inc (ANTX)
What is the current share price of AN2 Therapeutics Inc (ANTX) Today?
The share price of AN2 Therapeutics Inc (ANTX) is $5.48 (NASDAQ) as of 01-Sep-2026 16:00 EDT. AN2 Therapeutics Inc (ANTX) has given a return of -28.58% in the last 3 years.
What is the current PB & PE ratio of AN2 Therapeutics Inc (ANTX)?
Since, TTM earnings of AN2 Therapeutics Inc (ANTX) is negative, P/E ratio is not available.
The P/B ratio of AN2 Therapeutics Inc (ANTX) is 2.86 times as on 28-Aug-2026, a 45 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.98 |
0.65 |
2024 |
-0.80 |
0.50 |
2023 |
-9.41 |
4.89 |
2022 |
-4.46 |
1.94 |
2021 |
-- |
-- |
What is the 52 Week High and Low of AN2 Therapeutics Inc (ANTX)?
The 52-week high and low of AN2 Therapeutics Inc (ANTX) are Rs 7.19 and Rs 1.00 as of 02-Sep-2026.
What is the market cap of AN2 Therapeutics Inc (ANTX)?
AN2 Therapeutics Inc (ANTX) has a market capitalisation of $ 211 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in AN2 Therapeutics Inc (ANTX)?
Before investing in AN2 Therapeutics Inc (ANTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.